Company Filing History:
Years Active: 2007-2008
Title: Kevin Michael Ruley: Innovator in Antipsychotic Compounds
Introduction
Kevin Michael Ruley is a notable inventor based in Indianapolis, IN, who has made significant contributions to the field of pharmacology. He holds two patents that focus on innovative compounds aimed at treating psychotic disorders. His work is particularly relevant in the development of new medications that target dopamine receptors.
Latest Patents
Kevin's latest patents include the development of Piperazine substituted aryl benzodiazepines. These compounds are characterized by a complex formula that includes various aromatic rings and functional groups. They are designed to act as antagonists of the dopamine D2 receptor, providing potential therapeutic benefits for individuals suffering from psychosis and bipolar disorders. The patents also describe pharmaceutical formulations of these compounds, highlighting their importance in modern medicine.
Career Highlights
Kevin Michael Ruley is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development. His work at Eli Lilly has allowed him to focus on creating effective treatments for mental health disorders, contributing to the company's reputation for excellence in the pharmaceutical industry.
Collaborations
Throughout his career, Kevin has collaborated with esteemed colleagues such as Thomas Daniel Aicher and Zhaogen Chen. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.
Conclusion
Kevin Michael Ruley is a prominent figure in the field of pharmacology, with a focus on developing innovative treatments for psychotic disorders. His contributions through patents and collaborations underscore the importance of research in improving mental health therapies.